LADENBURG THALM/SH SH Raises Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target to $21.00

Corvus Pharmaceuticals (NASDAQ:CRVS) had its target price boosted by LADENBURG THALM/SH SH from $12.00 to $21.00 in a report released on Monday morning, Benzinga reports. LADENBURG THALM/SH SH currently has a buy rating on the stock.

Separately, StockNews.com raised shares of Corvus Pharmaceuticals from a sell rating to a hold rating in a report on Friday, September 13th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average target price of $10.83.

Corvus Pharmaceuticals Stock Performance

Corvus Pharmaceuticals stock opened at $5.48 on Monday. The firm’s fifty day moving average price is $3.57 and its 200-day moving average price is $2.47. The stock has a market cap of $342.78 million, a P/E ratio of -10.54 and a beta of 1.13. Corvus Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $6.15.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.05. During the same quarter in the previous year, the firm posted ($0.14) EPS. On average, analysts predict that Corvus Pharmaceuticals will post -0.45 earnings per share for the current year.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CRVS. Point72 Asset Management L.P. bought a new stake in Corvus Pharmaceuticals in the 2nd quarter worth $10,855,000. Samlyn Capital LLC grew its holdings in Corvus Pharmaceuticals by 160.7% in the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after acquiring an additional 3,774,658 shares during the last quarter. Vanguard Group Inc. grew its holdings in Corvus Pharmaceuticals by 10.6% in the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock worth $2,658,000 after acquiring an additional 142,724 shares during the last quarter. Marshall Wace LLP bought a new stake in Corvus Pharmaceuticals in the 2nd quarter worth $136,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Corvus Pharmaceuticals in the 2nd quarter worth $44,000. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.